|
Metastatic melanoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Transient Ischemic Attack
|
0.200 |
Therapeutic
|
disease |
RGD |
Neuroprotection against ischemic brain injury by knockdown of hematopietic progenitor kinase 1 expression.
|
18382279 |
2008 |
|
Transient Ischemic Attack
|
0.200 |
Therapeutic
|
disease |
RGD |
Tyrosine phosphorylation of HPK1 by activated Src promotes ischemic brain injury in rat hippocampal CA1 region.
|
18498770 |
2008 |
|
Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
To investigate the potential of pharmacological intervention using inhibitors of HPK1, we generated HPK1 kinase dead (KD) mice which carry a single loss-of-function point mutation in the kinase domain and interrogated the role of kinase activity in immune cells in the context of suppressive factors or the tumor microenvironment (TME).
|
30913212 |
2019 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, HPK1 has variety of roles in immunity, and is associated with the pathogenesis of autoimmune diseases, cancer, and the inflammatory response.
|
28901492 |
2017 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
HPK1 expression, axillary lymph node metastasis and tumor‑node‑metastasis (TNM) stage were identified as independent factors of overall survival (OS) in the ER‑positive group (P<0.05), and HPK1 positivity was associated with increased OS (P=0.048).
|
28765906 |
2017 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
T-cell-mediated immune responses and Th17-mediated experimental autoimmune diseases are enhanced in HPK1 knockout mice but ameliorated in GLK knockout mice.
|
26791862 |
2016 |
|
Autoimmune Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Inhibited expression of hematopoietic progenitor kinase 1 associated with loss of jumonji domain containing 3 promoter binding contributes to autoimmunity in systemic lupus erythematosus.
|
22014533 |
2011 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
We found that loss of HPK1 protein expression correlated significantly with the progression of pancreatic intraepithelial neoplasias (P = 0.001) and development of invasive PDA.
|
19141650 |
2009 |
|
Pancreatic carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Sunitinib, a multi-receptor tyrosine kinase (RTK) inhibitor approved for the management of gastrointestinal stromal tumors (GISTs), renal cell carcinoma (RCC), and pancreatic cancer, has been reported to inhibit HPK1 <i>in vitro</i> In this report, we describe the crystal structures of the native HPK1 kinase domain in both nonphosphorylated and doubly phosphorylated states, in addition to a double phosphomimetic mutant (T165E,S171E), each complexed with sunitinib at 2.17-3.00-Å resolutions.
|
31018963 |
2019 |
|
Malignant neoplasm of pancreas
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Sunitinib, a multi-receptor tyrosine kinase (RTK) inhibitor approved for the management of gastrointestinal stromal tumors (GISTs), renal cell carcinoma (RCC), and pancreatic cancer, has been reported to inhibit HPK1 <i>in vitro</i> In this report, we describe the crystal structures of the native HPK1 kinase domain in both nonphosphorylated and doubly phosphorylated states, in addition to a double phosphomimetic mutant (T165E,S171E), each complexed with sunitinib at 2.17-3.00-Å resolutions.
|
31018963 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Therefore, HPK1 has variety of roles in immunity, and is associated with the pathogenesis of autoimmune diseases, cancer, and the inflammatory response.
|
28901492 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Hematopoietic progenitor kinase 1 (HPK1) belongs to the mitogen activated protein kinase kinase kinase kinase (MAP4K) family of serine/threonine kinases, which have been associated with the incidence and progression of a variety of gastrointestinal malignant tumors in humans.
|
28765906 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Consistently, HPK1 levels are decreased in peripheral blood mononuclear cells and T cells from patients with psoriatic arthritis and systemic lupus erythematosus (SLE), respectively.
|
26791862 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, we observed a striking decrease in jumonji domain containing 3 (JMJD3) binding, but no marked change in enhancer of zeste homolog 2 (EZH2) binding, at the HPK1 promoter region in SLE CD4+ T cells compared to healthy controls.
|
22014533 |
2011 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Anti-miR-21 decreased protein expression of the tumour cell invasion mediators MAP4K1 and JNK, which are also known to be negatively regulated by PDCD4, and down-regulated integrin protein that is essential for MB leptomeningeal dissemination.
|
21775132 |
2011 |
|
Pancreatic carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Treatment of Panc-1 cells with a proteasome inhibitor, MG132, increased the HPK1 protein levels in a dose-dependent manner, suggesting that alteration in proteasome activity contributes to the loss of HPK1 protein expression in pancreatic cancer.
|
19141650 |
2009 |
|
Malignant neoplasm of pancreas
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Treatment of Panc-1 cells with a proteasome inhibitor, MG132, increased the HPK1 protein levels in a dose-dependent manner, suggesting that alteration in proteasome activity contributes to the loss of HPK1 protein expression in pancreatic cancer.
|
19141650 |
2009 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
MAP4K1 activity is functionally significant in invasion, as overexpression of a dominant negative MAP4K1 (dnMAP4K1) mutant in RKO cells inhibited not only c-Jun activation but also invasion.
|
16449643 |
2006 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, MAP4K1 down-regulation similarly inhibited GC progression.
|
31591939 |
2020 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, MAP4K1 down-regulation similarly inhibited GC progression.
|
31591939 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
PDIA6 is overexpressed in NSCLC and inhibits cisplatin-induced NSCLC cell apoptosis and autophagy via the MAP4K1/JNK/c-Jun signaling pathway, suggesting that PDIA6 may serve as a biomarker and therapeutic target for NSCLC patients.
|
30922965 |
2019 |
|
Renal Cell Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sunitinib, a multi-receptor tyrosine kinase (RTK) inhibitor approved for the management of gastrointestinal stromal tumors (GISTs), renal cell carcinoma (RCC), and pancreatic cancer, has been reported to inhibit HPK1 <i>in vitro</i> In this report, we describe the crystal structures of the native HPK1 kinase domain in both nonphosphorylated and doubly phosphorylated states, in addition to a double phosphomimetic mutant (T165E,S171E), each complexed with sunitinib at 2.17-3.00-Å resolutions.
|
31018963 |
2019 |
|
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
The expression of CDKN2B-AS1, BCL11A, and MAP4K1 was altered in lymphocytes extracted from patients with cerebral infarction.
|
30870006 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of <i>MAP4K3</i>, <i>MAP4K4</i>, and <i>MAP4K5</i> combined with low expression of MAP4K1 can serve as a sensitive tool to predict favorable overall survival in patients with acute myeloid leukemia.
|
31522654 |
2019 |